References
- Ding X, Med B, Alani AWG, Robinson JR. (2006). Extended-release and targeted drug delivery systems. In: Troy DB, eds., Remington: The Science and Practice of Pharmacy, Vol. 2. Easton, PA: Mack Publishing Co., 939–63.
- Chien YW, Lin S. (1997). Drug delivery: Controlled release. In: Swarbick J, Boylan JC, eds. Encylopedia of Pharmaceutical Technology 2nd ed., Vol. 1. New York: Marcel Dekker, Inc., 811–33.
- Weathrall DJ, Ledingham JGG, Warrell DA. (1996). Gastroenterology, Oxford Textbook of Medicine. 3rd ed. New York:Oxford Medical Publisher, 1936–43.
- Lewis C. (1999). Crohn's disease: new drug may help when others fail, U.S.F.D.A. Consumer Magazine.
- Rodriguez M, Vila-Jato JL, Jorres Doloves. (1998). Design of a new multiparticulate system for potential site specific and controlled drug delivery to the colonic region. J Control Release, 55:67–77.
- Krishnamacharia Y, Parshotam M, Senshang L. (2007). Development of pH and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm, 338:238–47.
- Gupta VK, Beckert TE, Deusch NJ, Harinaraon M, Price JC. (2001). A novel pH and time based multipotential colonic drug delivery system. I. Development. Int J Pharm, 213:83–91.
- Gao C, Huang J, Jiao Y, Shan L, Liu Y, Li Y, Mei X. (2006). In vitro release and in vivo absorption in beagles dogs of meloxicam from Eudragit FS30D coated pellets. Int J Pharm, 322:104–12.
- Chourasia MK, Jain SK. (2003). Pharmaceutical approaches to colon targeted drug delivery system. J Pharm Pharmaceut Sci, 6(1):33–66.
- Ibekwe VC, Kendall RA, Basit AW. (2004). Drug Delivery to the Colon. The Drug Delivery Companies Report, Spring/Summer, 27–30.
- Hu Z, Shimokawa T, Ohno T, Kimura G, Mawatari S, Kamitsuna M, Yoshikawa Y, Masuda S, Takada K. (1999). Characterization of norfloxacine release from tablet coated with a new pH sensitive polymer P-4135F. J Drug Target, 7:223–32.
- Rudolh MW, Klein S, Beckert TFE, Peterieit H, Dressman JB. (2001). A new 5 aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm, 51:183–90.
- Basit A, Bloor J. (2003). Perspectives on colonic drug delivery. Business Briefing:Pharmatech, 185–90.
- Iruin A, Fernandez-Arevalo M, Alvarez-Fuentes J, Fini A, Holgado MA. (2005). Elaboration and “in vitro” characterization of 5-ASA beads. Drug Develop Ind Pharm, 31:231–39.
- Cole ET, Scott RA, Alyson L, Conner AL. (2003). Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm, 231:83–95.
- Bott C, Rudolph MW, Schneider AR, Schirrmacher S, Skalsky B, Petereit HU, (2004). In vivo evaluation of a novel pH and time based multiunit colonic drug delivery systems. Aliment Pharmacol Ther, 1, 20:347–53.
- Tugcu-Demiroz F, Acartark F, Takka S, Konus-Bayunaga O. (2007). Evaluation of alginate based mesalazine tablets for intestinal drug delivery. Eur J Pharm Biopharm, 67:491–97.
- Huyghebaert N, Vermeire An, Remon JP. (2005). In vitro evaluation of coating polymers for enteric coating & human ileal targeting. Int J Pharm, 298:26–37.
- European Commission. (2000). Radiation Protecting 118 Referral Guidelines for Imaging. Luxembourg: Office for Official Publications of the European Commission Directorate-General for the Environment. http://ec.europa.eu/energy/nuclear/radioprotection/publication/doc/118_enpdf.
- Akhgari A, Garkeni HA, Sadeghi F, Azimaie M. (2005). Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Int J Pharm, 305:22–30.
- Nugent SG, Kumar D, Rampton DS, Evans DF. (2001). Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut Online, 48:571–77.